| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.028 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |